1.What is Cynosure’s ticker symbol?
 Cynosure is listed on the Nasdaq market under the symbol CYNO.

2.What is Cynosure’s strategy?
 We have a two-pronged business strategy: launching innovative new products and technologies for high-growth aesthetic applications developed through internal research and development and expanding our product offerings through acquisitions of complementary businesses and significant partnerships. Our research and development team works closely with opinion leaders and customers, both individually and through our sponsored seminars, to understand unmet needs and emerging applications in the field of aesthetic skin treatments and to innovate and develop new products and improvements to our existing products. They also conduct and coordinate clinical trials of our products. We believe we have a disciplined acquisition strategy that focuses on complementary product offerings, integrated distribution networks, return on investment and other strategic benefits.

3.How do aesthetic treatment lasers work?
 A laser is a device that creates and amplifies a coherent beam of light generally of one wavelength or a narrow band of wavelengths. Lasers have been used for medical and aesthetic applications since the 1960s. Intense pulsed light technology was introduced in the 1990s and uses flashlamps, rather than lasers, to generate incoherent light of multiple wavelengths, often referred to as a broadband of wavelengths. Both lasers and intense pulsed light devices can emit high energy light over varying pulse durations or time intervals.

By producing intense bursts of concentrated light, lasers and other light-based technologies selectively target melanin in hair follicles and pigmented lesions, hemoglobin in blood vessels and vascular lesions, water surrounding collagen in or below the dermis, ink in tattoos or fat tissue below the dermis. When the target absorbs sufficient energy, it becomes heated and/or mechanically disrupted to cause a biological reaction useful for treatment. The degree to which energy is absorbed in the skin depends upon the skin structure targeted—e.g., hair follicle or blood vessel—and the skin type—e.g., light or dark. Different types of lasers and other light-based technologies are needed to effectively treat the spectrum of skin types and conditions. As a result, an active aesthetic practice may require multiple laser or other light-based systems in order to offer treatments to its entire client base.

4.What does Cynosure consider its strategic advantages?
 We offer tailored customer solutions to address the market for non-invasive and minimally invasive laser and light-based aesthetic treatment applications, as well as RF energy based surgical and aesthetic applications. These solutions include non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health. We believe our laser and other light-based and RF systems are reliable, user friendly and easily incorporated into both physician practices and medi-spas. We complement our product offerings with comprehensive and responsive service offerings, including assistance with training, aesthetic practice development consultation and product maintenance. Among the factors that we believe enhance our market position:
  • Broad technology base
  • Expansive portfolio of aesthetic treatment systems
  • Additional energy sourced systems
  • Upgrade paths within product families
  • Global presence
  • Strong reputation over a 25-year history

5.What is the growth potential of your industry?
 Medical Insight, an independent industry research and analysis firm, estimated that in 2015 total sales of products in the global aesthetic market exceeded $7 billion. Medical Insight believes that total sales of products in the global aesthetic market will increase 11.8% annually through 2019.

6.How can I get more information on your products?
 For more information about Cynosure products, click here.

7.How do I purchase shares of Cynosure stock?
 Cynosure does not have a direct stock purchase plan. All trades must be made through a registered broker.

8.Does Cynosure pay dividends?
 Cynosure does not pay dividends on its common stock.

9.When does Cynosure’s fiscal year end?
 Cynosure is on a calendar year, with its year ending December 31.

10.When was Cynosure incorporated, and in which state?
 Cynosure was incorporated in Delaware in 1991.

11.Where are Cynosure’s headquarters?
 5 Carlisle Road
Westford, MA 01886
(978) 256-4200

12.How many employees does Cynosure have?
 As of December 31, 2016, Cynosure had 982 employees worldwide.

13.Who are Cynosure’s independent auditors?
 Cynosure retains Ernst & Young LLP as its independent auditor.

14.Who is Cynosure’s legal counsel?
 WilmerHale
60 State Street
Boston, Massachusetts 02109
(617) 526-6000

15.Which financial analysts cover Cynosure?
 For a list of Cynosure’s analysts, click here.

16.Who do I contact with questions about transferring shares, lost stock certificates and changes of address?
 These inquiries should be directed to our transfer agent:
American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY 10038
(800) 937-5449

17.Where can I get information about Cynosure’s management team and board of directors?
 Information about Cynosure’s management team and board of directors can be accessed in our Corporate Governance section.

18.How can I order an investor kit?
 You can request an investor kit or ask additional questions by visiting the Contact IR page.

19.When was Cynosure's IPO?
 Cynosure completed its initial public offering in December 2005.

20.Do you have any commercial distribution agreements with El.En. S.p.A.?
 We have several distribution agreements with El.En. Under one of these agreements, we purchase from El.En. its SmartLipo MPX system and its proprietary SLT II laser system. The SLT II laser system is an essential component of our SmartLipo Triplex, Cellulaze, and PrecisionTx systems, which also incorporate our proprietary software and delivery systems. We have exclusive worldwide rights under this agreement to sell the SmartLipo MPX system and our products containing the SLT II laser system. Under another distribution agreement with El.En. and separate distribution agreements with certain of our wholly owned subsidiaries in the United Kingdom, Germany and Spain, we purchase from El.En. its MonaLisa Touch laser system.